• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胶质母细胞瘤通过表观遗传免疫编辑获得髓系相关转录程序,从而引发免疫逃逸。

Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion.

机构信息

Centre for Regenerative Medicine, Institute for Regeneration and Repair, University of Edinburgh, 5 Little France Drive, Edinburgh EH16 4UU, UK; CRUK Edinburgh Centre, Institute of Genetics and Molecular Medicine, Crewe Road South, University of Edinburgh, Edinburgh EH42XR, UK.

Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London WC1E 6BT, UK.

出版信息

Cell. 2021 Apr 29;184(9):2454-2470.e26. doi: 10.1016/j.cell.2021.03.023. Epub 2021 Apr 14.

DOI:10.1016/j.cell.2021.03.023
PMID:33857425
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8099351/
Abstract

Glioblastoma multiforme (GBM) is an aggressive brain tumor for which current immunotherapy approaches have been unsuccessful. Here, we explore the mechanisms underlying immune evasion in GBM. By serially transplanting GBM stem cells (GSCs) into immunocompetent hosts, we uncover an acquired capability of GSCs to escape immune clearance by establishing an enhanced immunosuppressive tumor microenvironment. Mechanistically, this is not elicited via genetic selection of tumor subclones, but through an epigenetic immunoediting process wherein stable transcriptional and epigenetic changes in GSCs are enforced following immune attack. These changes launch a myeloid-affiliated transcriptional program, which leads to increased recruitment of tumor-associated macrophages. Furthermore, we identify similar epigenetic and transcriptional signatures in human mesenchymal subtype GSCs. We conclude that epigenetic immunoediting may drive an acquired immune evasion program in the most aggressive mesenchymal GBM subtype by reshaping the tumor immune microenvironment.

摘要

多形性胶质母细胞瘤(GBM)是一种侵袭性脑肿瘤,目前的免疫疗法方法都不成功。在这里,我们探讨了 GBM 中免疫逃避的机制。通过将 GBM 干细胞(GSCs)连续移植到免疫活性宿主中,我们发现 GSCs 通过建立增强的免疫抑制肿瘤微环境,获得了逃避免疫清除的能力。从机制上讲,这不是通过肿瘤亚克隆的遗传选择引起的,而是通过一种表观遗传免疫编辑过程,其中 GSCs 中的稳定转录和表观遗传变化在免疫攻击后被强制实施。这些变化引发了与髓样细胞相关的转录程序,导致肿瘤相关巨噬细胞的募集增加。此外,我们在人类间充质亚型 GSCs 中发现了类似的表观遗传和转录特征。我们得出结论,表观遗传免疫编辑可能通过重塑肿瘤免疫微环境,驱动最具侵袭性的间充质 GBM 亚型获得性免疫逃避程序。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/945ed35222ad/figs7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/dd07ef3e054d/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/0d6328cff6d3/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/70d16683a5f8/figs1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/1c9cdaf30182/figs2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/1dfdae040dc7/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/1d621bae644c/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/52e7a20e4cba/figs3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/50494ba8a0b6/figs4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/6023b02c9e06/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/f572f3f47741/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/28aae7a22d0c/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/ea5cdbdcc2f2/figs5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/c8c17c93fcd0/figs6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/5f7f4125c808/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/945ed35222ad/figs7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/dd07ef3e054d/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/0d6328cff6d3/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/70d16683a5f8/figs1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/1c9cdaf30182/figs2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/1dfdae040dc7/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/1d621bae644c/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/52e7a20e4cba/figs3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/50494ba8a0b6/figs4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/6023b02c9e06/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/f572f3f47741/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/28aae7a22d0c/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/ea5cdbdcc2f2/figs5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/c8c17c93fcd0/figs6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/5f7f4125c808/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b271/8099351/945ed35222ad/figs7.jpg

相似文献

1
Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion.胶质母细胞瘤通过表观遗传免疫编辑获得髓系相关转录程序,从而引发免疫逃逸。
Cell. 2021 Apr 29;184(9):2454-2470.e26. doi: 10.1016/j.cell.2021.03.023. Epub 2021 Apr 14.
2
Glioblastoma Stem Cells: MAP17 as a Novel Predictive Biomarker and Therapeutic Target Associated with Quiescence and Immune Evasion.胶质母细胞瘤干细胞:MAP17作为一种与静止和免疫逃逸相关的新型预测性生物标志物及治疗靶点
Discov Med. 2025 Jan;37(192):166-181. doi: 10.24976/Discov.Med.202537192.14.
3
The dual role of POSTN in maintaining glioblastoma stem cells and the immunosuppressive phenotype of microglia in glioblastoma.POSTN 在维持胶质母细胞瘤干细胞和小胶质细胞免疫抑制表型中的双重作用。
J Exp Clin Cancer Res. 2024 Sep 4;43(1):252. doi: 10.1186/s13046-024-03175-9.
4
Lactate reprograms glioblastoma immunity through CBX3-regulated histone lactylation.乳酸通过 CBX3 调节的组蛋白乳酰化重编程胶质母细胞瘤免疫。
J Clin Invest. 2024 Nov 15;134(22):e176851. doi: 10.1172/JCI176851.
5
Hypoxia-induced TREM1 promotes mesenchymal-like states of glioma stem cells via alternatively activating tumor-associated macrophages.缺氧诱导的TREM1通过交替激活肿瘤相关巨噬细胞促进胶质瘤干细胞的间充质样状态。
Cancer Lett. 2024 May 28;590:216801. doi: 10.1016/j.canlet.2024.216801. Epub 2024 Mar 11.
6
Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma.单细胞和患者队列的表达谱分析鉴定出胶质母细胞瘤中的多种免疫抑制途径和改变的 NK 细胞表型。
Clin Exp Immunol. 2020 Apr;200(1):33-44. doi: 10.1111/cei.13403. Epub 2019 Dec 16.
7
Glioblastoma Stem Cells at the Nexus of Tumor Heterogeneity, Immune Evasion, and Therapeutic Resistance.肿瘤异质性、免疫逃逸和治疗抗性交汇处的胶质母细胞瘤干细胞
Cells. 2025 Apr 9;14(8):562. doi: 10.3390/cells14080562.
8
Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.联合表达分析、生物信息学和靶向蛋白质组学鉴定胶质母细胞瘤干细胞中的新潜在治疗靶点。
Oncotarget. 2015 Sep 22;6(28):26192-215. doi: 10.18632/oncotarget.4613.
9
Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments.对胶质母细胞瘤肿瘤、BTIC 和异种移植物进行全面基因组分析,揭示了其在生长环境中的稳定性和适应性。
Proc Natl Acad Sci U S A. 2019 Sep 17;116(38):19098-19108. doi: 10.1073/pnas.1813495116. Epub 2019 Aug 30.
10
Elevated α-1,2-mannosidase MAN1C1 in glioma stem cells and its implications for immunological changes and prognosis in glioma patients.脑胶质瘤干细胞中 α-1,2-甘露糖苷酶 MAN1C1 的上调及其对脑胶质瘤患者免疫变化和预后的影响。
Sci Rep. 2024 Sep 27;14(1):22159. doi: 10.1038/s41598-024-72901-2.

引用本文的文献

1
Axonal injury is a targetable driver of glioblastoma progression.轴突损伤是胶质母细胞瘤进展的一个可靶向驱动因素。
Nature. 2025 Aug 20. doi: 10.1038/s41586-025-09411-2.
2
Epigenetic regulation of cancer stemness.癌症干性的表观遗传调控。
Signal Transduct Target Ther. 2025 Aug 1;10(1):243. doi: 10.1038/s41392-025-02340-6.
3
A novel organoid model retaining the glioma microenvironment for personalized drug screening and therapeutic evaluation.一种保留胶质瘤微环境用于个性化药物筛选和治疗评估的新型类器官模型。

本文引用的文献

1
Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity.发育和损伤反应转录状态梯度定义了支持胶质母细胞瘤异质性的功能脆弱性。
Nat Cancer. 2021 Feb;2(2):157-173. doi: 10.1038/s43018-020-00154-9. Epub 2021 Jan 4.
2
Bystander IFN-γ activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment.旁观者 IFN-γ 活性促进广泛而持续的细胞因子信号转导,改变肿瘤微环境。
Nat Cancer. 2020 Mar;1(3):302-314. doi: 10.1038/s43018-020-0038-2. Epub 2020 Mar 9.
3
Long-distance modulation of bystander tumor cells by CD8 T cell-secreted IFNγ.
Bioact Mater. 2025 Jul 14;53:205-217. doi: 10.1016/j.bioactmat.2025.07.015. eCollection 2025 Nov.
4
IDENTIFICATION OF DISEASE-SPECIFIC VULNERABILITY STATES AT THE SINGLE-CELL LEVEL.单细胞水平上疾病特异性脆弱状态的识别。
bioRxiv. 2025 Jun 8:2024.12.04.626873. doi: 10.1101/2024.12.04.626873.
5
Interactions between glioblastoma and myeloid cells.胶质母细胞瘤与髓样细胞之间的相互作用。
Front Cell Dev Biol. 2025 Jun 24;13:1632122. doi: 10.3389/fcell.2025.1632122. eCollection 2025.
6
Advances in Cellular Immune Theranostic Approaches for Glioblastoma: Current Trends and Future Directions.胶质母细胞瘤细胞免疫治疗诊断方法的进展:当前趋势与未来方向
Cancer Innov. 2025 Jul 3;4(4):e70018. doi: 10.1002/cai2.70018. eCollection 2025 Aug.
7
Transglutaminase 2 function in glioblastoma tumor efferocytosis.转谷氨酰胺酶2在胶质母细胞瘤肿瘤细胞清除中的作用。
Cell Death Dis. 2025 Jul 3;16(1):487. doi: 10.1038/s41419-025-07819-2.
8
TRIM21 functions as an oncogene in glioblastoma by transactivating FOSL1 and promoting the ubiquitination of p27.TRIM21通过反式激活FOSL1并促进p27的泛素化,在胶质母细胞瘤中作为一种癌基因发挥作用。
Cell Commun Signal. 2025 Jul 1;23(1):313. doi: 10.1186/s12964-025-02325-6.
9
Emerging Chemotherapy Targets: Insights from Advances in Glioma Treatment.新兴的化疗靶点:胶质瘤治疗进展的见解
Biomedicines. 2025 Jun 12;13(6):1452. doi: 10.3390/biomedicines13061452.
10
Recent advances in molecular mechanisms of microRNAs in pathogenesis and resistance of treatment in glioblastoma.微小RNA在胶质母细胞瘤发病机制及治疗耐药性中的分子机制研究进展
Clin Transl Oncol. 2025 Jun 24. doi: 10.1007/s12094-025-03969-z.
CD8 T 细胞分泌的 IFNγ 对旁观者肿瘤细胞的远程调节。
Nat Cancer. 2020 Mar;1(3):291-301. doi: 10.1038/s43018-020-0036-4. Epub 2020 Mar 9.
4
Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells.脑肿瘤微环境景观的剖析揭示了免疫细胞的疾病特异性改变。
Cell. 2020 Jun 25;181(7):1643-1660.e17. doi: 10.1016/j.cell.2020.05.007. Epub 2020 May 28.
5
The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment.髓系来源的抑制性细胞在胶质瘤免疫抑制微环境中的新作用。
Front Immunol. 2020 Apr 24;11:737. doi: 10.3389/fimmu.2020.00737. eCollection 2020.
6
Midkine activation of CD8 T cells establishes a neuron-immune-cancer axis responsible for low-grade glioma growth.中期因子激活 CD8 T 细胞建立了一个神经元-免疫-癌症轴,负责低级别神经胶质瘤的生长。
Nat Commun. 2020 May 1;11(1):2177. doi: 10.1038/s41467-020-15770-3.
7
Tumor-Specific T Cell Activation in Malignant Brain Tumors.恶性脑肿瘤中的肿瘤特异性 T 细胞激活。
Front Immunol. 2020 Feb 13;11:205. doi: 10.3389/fimmu.2020.00205. eCollection 2020.
8
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma.人类肿瘤的免疫分析鉴定 CD73 为胶质母细胞瘤的组合靶标。
Nat Med. 2020 Jan;26(1):39-46. doi: 10.1038/s41591-019-0694-x. Epub 2019 Dec 23.
9
The Phenotypes of Proliferating Glioblastoma Cells Reside on a Single Axis of Variation.增生性胶质母细胞瘤细胞的表型位于单一变化轴上。
Cancer Discov. 2019 Dec;9(12):1708-1719. doi: 10.1158/2159-8290.CD-19-0329. Epub 2019 Sep 25.
10
Experimental models and tools to tackle glioblastoma.用于攻克胶质母细胞瘤的实验模型和工具。
Dis Model Mech. 2019 Sep 6;12(9):dmm040386. doi: 10.1242/dmm.040386.